Triple-negative breast cancer(TNBC)is one of the prognosis poorer molecular subtypes of breast cancer with limited conventional treatments,however,it is characterized by a strong immune microenvironmental activity,which provides a certain biological basis for immunotherapy as well as antibody-drug conjugates(ADCs).Nowadays,the combination of immune checkpoint inhibitors and chemotherapy,as well as the successive introduction of ADCs such as sacituzumab govitecan and trastuzumab deruxtecan,has changed the therapeutic pattern of TNBC and provided new ideas for the development of new drugs for TNBC.In this paper,the clinical research progress of immunotherapy and ADCs for the treatment of TNBC is reviewed,in order to provide a reference for the strategy selection of clinical drugs,that is,the future research and development trend.
关键词
三阴性乳腺癌/免疫治疗/抗体偶联药物/临床试验/免疫检查点抑制剂/化疗
Key words
Triple-negative breast cancer/Immunotherapy/Antibody-drug conjugates/Clinical trials/Immune checkpoint inhibitors/Chemotherapy
维普
万方数据